Bioxodes SA

Bioxodes is a clinical-stage biotech company developing therapeutics for patients with (thrombo)inflammatory diseases.

[Bioxodes SA @bioxodes]

Excited to announce Bioxodes will attend #ISC2025 (Feb 5–7)! Valérie Pireaux will present preclinical data on BIOX-101, targeting intracerebral hemorrhage — an unmet need in stroke care.

Let’s connect at ISC! 🚀

#StrokeCare #Innovation #Bioxodes #ISC2025

[Bioxodes SA @bioxodes]

Full house @BrainDays ! Our CMO, Dr. Hans Warrinnier, delivered a high-impact pitch on BIOX-101 at #BrainInnovationDays, highlighting our solution for unmet medical needs. Honored to be selected to pitch & showcase a poster among top innovators!

#BIOX101 #strokecare #Bioxodes

[Bioxodes SA @bioxodes]

Very much looking forward to attending the @BrainDays and to share our innovation through a poster presentation! Let's meet in Brussels and talk about brain health. #voiceofstroke #ICH #strokecare

[Bioxodes SA @bioxodes]

Some of the most exciting therapies in the future could come from animals @Labiotech_eu
Interesting read and thank you for mentioning @bioxodes !
#Biotech #Innovation #Healthcare #LifeSciences #Belgium #ticksaliva #stroke #voiceofstroke

https://t.co/MCApber3dk

[BioWin @BioWin_asbl]

@bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation. https://t.co/gc9Jn0SnFB

[Bioxodes SA @bioxodes]

#BioEquity 2024 is just around the corner! @EBDgroup @BioCentury

Our CEO is looking forward to present Bioxodes' progress and vision to potential investors. See you in San Sebastian!
#Bioxodes #BioEquity24

[Bioxodes SA @bioxodes]

Exciting news! Our CEO, Marc Dechamps, will be sharing latest updates on BIOX-101 (Ir-CPI), our groundbreaking therapy for intracerebral hemorrhage on several conferences. https://t.co/4K30Mzg7Vz #EITSummit #Sachs_ELSF #LSXWorld #BioEquity

[Bioxodes SA @bioxodes]

Our CEO Marc Dechamps will be presenting at the upcoming #biotechshowcase in #SanFrancisco ! Curious to hear more about our latest developments? See you there! @EBDgroup #JPMorgan

[Bioxodes SA @bioxodes]

Prepping for #bioeurope, our CEO Marc Dechamps is all set for #partnering! Our mission to advance healthcare solutions for #stroke is stronger than ever! #IrCPI
@EBDgroup

[Bioxodes SA @bioxodes]

Proud to share that our CEO Marc Dechamps, has been awarded with the 'Biotechnology CEO of the Year - Europe' title at the 2023 Business Worldwide Magazine CEO Awards! 🏆
Full PR https://t.co/dJ8pCpEZ9f

[Bioxodes SA @bioxodes]

🌟 Exciting Update! We presented our groundbreaking research on Ir-CPI at #ISTH2023. Revolutionizing #thrombosis treatment and #neuroinflammation!
@isth HealthcareInnovation #Bioxodes

[Bioxodes SA @bioxodes]

🔻 MEDIA ARTICLE 🔺

Could a bioactive peptide secreted in the saliva of ticks offer a useful therapy for people who have experienced #intracerebral #hemorrhage (#ICH)?

Read the interview of our CEO, Marc Dechamps by @BioWorld here👇
https://t.co/8UkCTxIohr

[Bioxodes SA @bioxodes]

@isth

[Bioxodes SA @bioxodes]

Join us at @ISTH2023 in Montreal!
We present a poster on our lead candidate Ir-CPI, a first-in-class drug candidate against #thrombosis and #neuroinflammation starting with #hemorrhagic #stroke.
https://t.co/dlCpjeD2Ta

[Bioxodes SA @bioxodes]

Last week, @bioxodes  was in Munich, Germany, to attend the 9th European Stroke Organization Conference (#ESOC2023).
Valérie Pireaux, Preclinical Scientist, presented data on Ir-CPI in a model of intracerebral hemorrhage.
You can view the poster here:
🧠 https://t.co/1QdUF994qt

[Bioxodes SA @bioxodes]

Part of Bioxodes' team is attending #ESOC2023.

👉 Reach us if you want to know more about our drug candidate Ir-CPI in intracerebral haemorrhage.

You can also consult our e-poster on-site

[Bioxodes SA @bioxodes]

Yesterday our Clinical Project Manager Charlotte Corbisier did a great job presenting at #ESOTA!
She explained our approach, as a small biotech company, to a phase IIa trial on Ir-CPI.

Stay tuned for more news coming soon!
#stroke #strokeprevention #voiceofstroke #ESOC2023

[Bioxodes SA @bioxodes]

Join us at the #ESOC2023 organised by @ESOstroke! The @bioxodes team will give multiple presentations on our lead candidate #Ir-CPI and the important progress we made since inception! #stroke #brainthrombosis #neuroinflammation

[Andrew Lloyd ALA @ALA_Group]

[ALA Client News] @bioxodes presents latest developments at key international conferences - on first-in-class drug candidate for patients with intracerebral hemorrhage

👉https://t.co/EYn8V9Ep6N

@BioCentury @ESOstroke @isth
#conferences #BioEquity2023 #ESOC2023 #ISTH2023

[Bioxodes SA @bioxodes]

PRESS RELEASE
Interesting times for @bioxides! Meet us at the following conferences @BioEquity @EBDgroup @isth @esocstroke
PR: https://t.co/BH8rByKpyr